Inari Medical, Inc. (NASDAQ: NARI) reported Q2 EPS of ($0.16), $0.02 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $25.4 million versus the consensus estimate of $13.15 million.

Second Quarter Highlights:

• Treated more patients in the second quarter of 2020 than in the first quarter of 2020, despite COVID-19 headwinds
• Reported revenue of $25.4 million in the second quarter of 2020, a 152% increase over the same quarter last year
• Established a weekly online educational series, the Clot Warrior Academy, attended to date by more than 600 physicians and 200 nurses and technicians
• Completed an initial public offering of 9.4 million shares, raising $163.0 million in net proceeds

“The second quarter was difficult for so many companies and so many people, for all the reasons we know. Our team has responded to the challenges and risen to the occasion. Our employee training and physician education programs are better, our supply chain and production capacity are more robust, our pipeline is broader and deeper, and our relationships with our physicians, customers, and with each other are stronger than before the pandemic. Importantly, our team and physician partners found a way to treat more patients in the second quarter than in any previous quarter. In these humbling and uncertain times, we are thankful for the clarity of a mission and a cause bigger than ourselves and business,” said Bill Hoffman, Chief Executive Officer.

For earnings history and earnings-related data on Inari Medical, Inc. (NARI) click here.